ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
129
HLB seeks approval for liver cancer drug with US FDA
admin
2023.05.23
128
HLB ends split-off of ship business to focus on bio sector
admin
2023.04.21
127
HLB Cell produces extracellular matrix Hutrigel
admin
2023.04.06
126
HLB's US subsidiary promotes efficacy of liver cancer drug Rivoceranib
admin
2023.03.27
125
PSMC emerges as core of HLB Group interested in CAR-T drugs
admin
2023.03.07
124
HLB's anticancer drug receives greenlight in China
admin
2023.02.02
123
HLB set to apply for conditional domestic approval of rivoceranib
admin
2022.11.09
122
HLB completes preparatory meeting with FDA for approval of liver cancer drug
admin
2022.10.14
121
Elevar Therapeutics Announces Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option
admin
2022.10.13
120
Clinical Trial Results Allude to New Options for Patients With HCC
admin
2022.10.07
1
2
3
4
5
6
7
8
9
10
>
>>